The Economics of Innovation: Optimizing Clinical Trial Investments with Robert Gabriel, Ashur Capital

About the Interviewee

Robert Gabriel is a Board Member and Managing Partner at Ashur Capital.

Robert Gabriel, Ph.D., MBA, is Managing Partner and Board Member of Ashur Capital, a private equity and venture capital firm headquartered in New York City, USA. With a 30-year career spanning specialty chemicals, consumer products, and higher education, he has built a reputation as an innovation-driven executive with an exceptional ability to translate scientific insight and market foresight into scalable business success. At Ashur Capital, Dr. Gabriel leads strategic direction, capital deployment, and portfolio growth, guiding early-stage ventures across emerging technology and industrial sectors through informed, data-driven investment decisions.

Dr. Gabriel began his career in research and development at Unilever, where he managed R&D initiatives for detergent and surfactant technology across European markets. His early success in technical leadership led to advanced roles at Procter & Gamble and Church & Dwight, where he directed cross-functional teams responsible for landmark product launches in men’s personal care and oral hygiene. At Rhodia (acquired by Solvay) and later The Clorox Company, he transitioned into global business and R&D leadership, driving product innovation, capacity expansion, and cost optimization strategies that improved operational efficiency and positioned brands for sustained market leadership.

As Vice President of Sales and Marketing at MeadWestvaco (MWV) (became Westrock after the merger with RockTenn), Dr. Gabriel managed business units exceeding $110 million in revenue, introducing advanced packaging and formulation solutions for the pharmaceutical and cosmetics industries. He went on to found Genesis Aromatique, a specialty chemicals and fragrance company, where he served as President and CEO for five years—spearheading strategic innovation, partnership development, and capital acquisition. Later, as Campus Director for the University of Phoenix, he applied his leadership and analytical acumen to higher education, overseeing academic quality, market growth, and community partnerships across Chicago-area campuses.

At Ashur Capital, Dr. Gabriel combines his corporate and entrepreneurial expertise to identify high-value opportunities in industrial innovation, specialty manufacturing, and AI-driven commercialization. His strategic strengths lie in business development, financial management, productivity optimization, and performance improvement, underpinned by a deep understanding of scientific innovation cycles.

Dr. Gabriel holds a Doctor of Philosophy (Ph.D.) in Chemistry from the University of Illinois Chicago and an MBA from The Wharton School of the University of Pennsylvania. A certified Accredited Investor with Parallel Markets, he remains an active mentor to emerging business leaders and a vocal advocate for bridging scientific R&D with commercial growth. His career reflects a lifelong commitment to advancing sustainable innovation, competitive excellence, and enterprise transformation across global industries.

The Discussion

From Molecules to Markets: The Business Science Behind Clinical Trial Efficiency

[Engr. Dex Marco]: It’s such a pleasure to have you here with us, Dr. Gabriel. So, Robert, with your dual background in chemistry and business, you stand at the intersection of scientific rigor and financial strategy. Clinical trials are both capital intensive and high-risk ventures. Could you share how your scientific and managerial expertise converge at Ashur Capital to identify, assess, and optimize opportunities that improve clinical trial cost-efficiency while ensuring scientific integrity?

[Dr. Robert]: Thank you for having me, Dex. Certainly! My dual expertise in chemistry and business allows me to approach clinical trial opportunities with a comprehensive perspective. At Ashur Capital, I leverage scientific rigor to thoroughly evaluate the methodological soundness, regulatory compliance, and potential impact of clinical trials. Meanwhile, my business acumen helps in assessing the financial viability, risk management, and strategic alignment of each opportunity.

By combining these skill sets, I can identify promising opportunities by analyzing scientific data to ensure a high likelihood of success, assess cost-efficiency through detailed financial modeling, identifying areas for cost reduction without compromising scientific integrity, optimize trial design by recommending innovative, decentralized, or adaptive methodologies that reduce costs and accelerate timelines, ensure scientific integrity by maintaining rigorous oversight of trial protocols, quality standards, and regulatory adherence, negotiate partnerships and funding structures that balance risk and reward, maximizing resource allocation.

This integrated approach ensures that we pursue high-quality clinical programs that are financially sustainable and scientifically robust, ultimately driving faster, more efficient paths to valuable medical advancements.

Intelligent Design: Rethinking the Structure of Clinical Trials

[Dex]: The architecture of a trial often dictates its cost, duration, and eventual success. Adaptive designs, decentralized frameworks, and data-driven modeling are transforming how trials are conceived. From your vantage point, what are the most effective strategies today for designing trials that deliver robust outcomes with minimized financial and operational overhead?

[Robert]: The most effective strategies today, in my opinion, for designing trials that balance robustness with cost-efficiency include:

Adaptive Trial Designs. Incorporating flexibility into trial protocols allows real-time modifications, such as dose adjustments, cohort expansions, or early stopping, based on interim data. This reduces resource waste and accelerates decision-making.

Decentralized and Virtual Trials. Utilizing remote monitoring, telemedicine, and local healthcare providers minimizes site costs, improves patient recruitment, and enhances participant retention, leading to faster and more cost-effective studies.

Data-Driven Modeling and Simulation. Applying advanced analytics, machine learning, and biostatistical modeling pre-trial helps optimize sample size, endpoints, and patient stratification, reducing the risk of costly redesigns or failures.

Use of Digital Technologies and Wearables. Continuous data collection through digital tools improves data quality, reduces the need for frequent site visits, and offers real-time insights, which streamline trial operations.

Strategic Partnering and Resource Sharing. Collaborating with CROs, academic institutions, and technology providers can spread costs, access expertise, and leverage innovative platforms.

Integrated Protocol Design. Ensuring protocols are streamlined, with clear endpoints and minimal redundancies, minimizes delays and operational complexity.

By integrating these strategies, trials become more resilient, scalable, and economically sustainable while maintaining scientific rigor, ultimately increasing the likelihood of robust outcomes within a constrained budget.

Clients at the Core: Mapping the Alithia Engagement Experience

[Dex]: The integration of AI, predictive analytics, and digital platforms has fundamentally changed how clinical operations are monitored and managed. How does Ashur Capital evaluate and invest in technology-driven innovations that enhance efficiency, accelerate timelines, and reduce costs across the clinical development spectrum?

[Robert]: At Ashur Capital, evaluating and investing in technology-driven innovations involves a rigorous, multi-faceted approach that aligns scientific validity with strategic value. Our process includes:

Assessing Scientific and Technical Merits. We thoroughly review the underlying AI algorithms, data integrity, validation studies, and regulatory considerations to ensure technological robustness and compliance.

Evaluating Impact on Clinical Operations. We analyze how the technology improves key areas such as patient recruitment and retention, data collection accuracy, real-time monitoring, and adaptive trial capabilities to ensure tangible efficiency gains.

Analyzing Cost-Benefit Dynamics. We scrutinize potential reductions in operational overhead, shortened timelines, and decreased trial failure rates against the investment costs, ensuring favorable ROI and scalability.

Reviewing Strategic Fit and Market Potential. We consider the company’s alignment with evolving industry standards, its differentiation in the marketplace, and its potential to set new benchmarks in clinical development.

Conducting Pilot Programs and Due Diligence. Whenever possible, we support pilot implementations to validate performance and integration with existing systems, followed by comprehensive due diligence before committing to larger investments.

Supporting Regulatory and Data Security Compliance. Ensuring the innovation complies with GDPR, HIPAA, FDA, and other relevant regulations is non-negotiable in our evaluation.

By combining scientific rigor with strategic foresight, Ashur Capital invests in technologies that not only enhance immediate operational efficiency but also foster long-term advancements in clinical development, ultimately reducing costs and accelerating the delivery of new therapies

The Human Element: Enhancing Patient Recruitment and Retention

[Dex]: Recruitment bottlenecks remain one of the most expensive pain points in clinical research. Advances in digital outreach and patient engagement platforms are beginning to reshape this space. What novel approaches or partnerships have you seen succeed in improving patient recruitment, retention, and diversity, while maintaining ethical and data-driven rigor?

[Robert]: I can think of seven. First is decentralized and hybrid clinical trial models. Decentralized Clinical Trials (DCTs) reduce the burden on participants by minimizing or eliminating the need for in-person visits to a research site.

Key features. Technologies such as mobile apps, telehealth, e-consent, and wearable biosensors are used for remote monitoring and data collection.
Benefits. This approach expands access for people in remote or underserved areas, improves convenience, and can lead to higher retention rates.
Example. In a remote hybrid trial, a study team could use telehealth for routine check-ins, while local labs and home health visits cover necessary blood draws and physical exams.

Second is artificial intelligence and machine learning. AI and ML analyze vast datasets to optimize recruitment strategies and identify eligible participants with greater precision.

Predictive analytics. AI can analyze sources like electronic health records (EHRs) and patient registries to forecast which individuals are most likely to meet trial eligibility criteria.
Optimized outreach. Algorithms help refine targeted digital ad campaigns on platforms like Google and social media by testing what messaging and imagery resonates best with specific demographics.
Ethical rigor. To maintain ethical standards, robust governance and privacy measures must be in place to handle sensitive patient data. All ad copy requires approval from an Institutional Review Board (IRB).

Third is patient-centric protocol design. Involving patients directly in the trial design process is a powerful strategy for increasing relevance, enrollment, and retention.
Patient advisory boards. Engaging patients and advocacy groups as co-creators in the protocol design phase ensures the study outcomes and procedures are meaningful and manageable.
Reduced participant burden. This feedback helps simplify inclusion/exclusion criteria and consolidate visit schedules, which are common reasons for patient dropout.

Fourth is innovative partnerships to improve diversity and collaborations with community organizations. Partnerships with local community groups, such as Federally Qualified Health Centers (FQHCs) and faith-based organizations, help build trust and address historical mistrust in underrepresented communities.
Shared resources and expertise. Sponsors and research sites can gain vital insights into community needs and work with trusted community leaders to reach potential participants.

Reciprocity. To be effective and ethical, these partnerships must be mutually beneficial and sustained beyond a single trial, which builds a foundation of long-term trust.

Fifth is diversity-focused technology platforms. Emerging companies and platforms specialize in addressing recruitment and diversity challenges using technology-driven approaches.
Acclinate. The company uses data-driven strategies and partnerships to build trust within communities of color to improve clinical trial diversity.
Studypages. This platform provides tools for patient-centric trial design and management, including features to track diversity goals and create tailored educational resources.

Penultimately, we have stakeholder collaboration across the ecosystem. The FDA emphasizes a multi-stakeholder approach to increasing diversity, which coordinates efforts across sponsors, research sites, and patient groups.
Diverse research teams. Diversifying research staff, from investigators to coordinators, can improve cultural competency and build rapport with underrepresented participants.
Targeted strategies. In one study across five health systems, using electronic outreach (email and patient portal) recruited a higher proportion of Black patients for a bariatric surgery trial compared to postal mail.

Lastly is maintaining ethical and data-driven rigor and ensuring accessibility and minimizing bias. While digital tools offer immense potential, strategies must be implemented to prevent inadvertently widening the “digital divide” and excluding participants.

Multichannel outreach. Combining digital methods with traditional outreach, like community events, flyers, and physician referrals, ensures recruitment remains inclusive.
Bias mitigation. The use of AI must be carefully governed. For example, strategies like A/B testing recruitment messages should focus on improving engagement, not exploiting biases.

Streamlined Execution: From Oversight to Outcome

[Dex]: Operational inefficiencies, from data silos to vendor misalignments, can erode both budgets and timelines. In your experience, what practical process-level interventions, whether in governance, vendor integration, or project management, yield the most measurable impact in trial cost and ROI optimization?

[Robert]: Based on common industry challenges and best practices, the following process-level interventions in governance, vendor integration, and project management yield the most measurable impact on trial cost and ROI optimization.

Governance. Ineffective data governance can increase costs through poor data quality, compliance issues, and manual processes.
Establish a strong data governance framework. Clearly define roles and responsibilities for data management across the organization and with external vendors.
Centralize data management. Use a single, integrated eClinical platform toconsolidate data from multiple systems. This eliminates data silos, reduces transcription errors, and enables better real-time decision-making.
○ Measurable impact: Automating data quality checks and reducing manual data remediation can decrease compliance-related IT costs by 30% or more and lower data errors by 20–40%.

Automate compliance and risk management. Use an AI-powered content services platform to automate the classification and processing of patient records, which helps maintain compliance with regulations like HIPAA and GDPR.

Vendor integration. Poor vendor management and misalignment with contract research organizations (CROs) can lead to significant delays and cost overruns.
Move from a transactional to a strategic partnership model. Select vendors based on long-term value, not just cost. By sharing goals and data across multiple trials, partners gain a deeper understanding of the sponsor’s needs, leading to better outcomes.
Align commercial and cultural expectations. Be transparent about your company culture and preferred way of working. This enables the CRO to assemble the right team and approach, fostering a collaborative partnership rather than just a client-vendor relationship.
○ Measurable impact: Evaluating and selecting partners for long-term collaboration can save costs in the long run by preventing delays and ensuring higher quality outcomes.

Implement integrated technology. Ensure that vendors utilize technology that integrates seamlessly with your existing systems. For example, a robust Clinical Trial Management System (CTMS) can provide a centralized data system accessible to both the research site and sponsor, speeding up information flow and risk mitigation.

Project management. Upfront planning, risk mitigation, and proactive monitoring are crucial for managing trial timelines and budgets.
Create detailed, realistic project plans. Develop a comprehensive plan at the outset that includes a timeline of milestones, key dates, and resource allocation. Account for and actively mitigate common risks, such as patient recruitment delays.
○ Measurable impact: A detailed project plan helps prevent “scope creep,” which drains resources and delays trials.

Embrace digital tools and adaptive design. Use technology like Electronic Data Capture (EDC) and Clinical Trial Management Systems (CTMS) for real-time monitoring and data collection. Consider adaptive trial designs, which allow for modifications based on emerging data, reducing resource drain and shortening trial durations.
○ Measurable impact: Studies show that incorporating AI into data management has reduced trial duration by 50%.

Prioritize patient-centric approaches. Design trials with the patient in mind to improve engagement and retention, which directly impacts trial timelines and costs.
○ Measurable impact: Higher patient retention rates reduce the need for additional recruitment efforts, avoiding costly delays. Utilizing electronic patient-reported outcomes (ePRO) tools can provide higher-quality, real-world data more efficient.

Capital Confidence: Aligning Investor Expectations with Scientific Reality

[Dex]: Investors often demand measurable returns within tight timelines, yet drug development remains inherently uncertain. How do you balance investor expectations with the unpredictable nature of R&D, and what communication or evaluation frameworks do you employ to keep both scientific teams and investors aligned toward shared value creation?

[Robert]: Striking a balance between investor demands for measurable returns and the inherent uncertainties of drug development requires disciplined communication and specific frameworks for evaluation. By focusing on data-driven, strategic storytelling, companies can build trust and manage expectations even in the face of scientific ambiguity.

Communication Strategies for Balancing Expectations

Define and communicate the long-term value proposition
Focus on the “why”. Frame the company’s work around the significant unmet medical needs being addressed. Investors need to understand the big picture, including the potential market size and patient impact, not just technical data.
Emphasize scientific differentiation. Highlight your core scientific strengths, such as a novel mechanism of action, first-in-class potential, or unique technological platform. This shifts the focus from a single timeline-driven asset to the company’s overall innovative capability and long-term potential.

Implement transparent, targeted communication
Communicate often, but selectively. Provide consistent, targeted updates to investors on significant developments. Avoid overwhelming them with unnecessary scientific minutiae. Keep communication focused on the most critical milestones and decisions.
Be honest about uncertainty. Drug development is risky, and investors are aware of this. Hiding setbacks or negative feedback can erode trust. Instead, transparently discuss identified risks, the potential impact, and your mitigation plans.
Use visual storytelling. Translate complex data and development plans into easily digestible visual aids, such as charts, infographics, and visual roadmaps. A visual framework can level-set investor expectations by clearly showing the scope of the development program and key milestones.

Tailor the message to different investor profiles
Understand your audience. Recognize that different investors have different priorities. Tailor the message to each group’s interests. For instance, a mission-aligned fund may focus on patient impact, while a generalist fund is more interested in scalability and commercial strategy.
Leverage FDA feedback. Use interactions with regulatory bodies like the FDA to demonstrate due diligence. Highlight positive feedback or explain how you are addressing any concerns raised, which builds investor confidence by showcasing a credible, data-driven strategy.

Evaluation Frameworks for Alignment

Milestone-based valuation and funding
Structure financing in stages. Raise funds in stages tied to specific, agreed-upon milestones (e.g., preclinical data, Phase 1 trial completion). This allows investors to evaluate progress and de-risk their investment at key inflection points before committing more capital.
Identify value inflection points. Clearly define the critical milestones that will significantly increase the drug candidate’s value. For instance, successfully demonstrating a drug’s safety in a Phase 1 trial is a crucial de-risking event that investors can measure.

Risk-adjusted net present value (rNPV)
Quantify financial projections. Use the rNPV framework to project the drug’s potential value based on the estimated market size, sales, and development costs. Critically, this framework factors in the probability of success for each development phase.
Compare investment scenarios. Generate scenarios that show the trade-offs between time, cost, risk, and return for different development paths. This allows both the scientific team and investors to make properly informed decisions about resource allocation.

Team science and trust-building
Invest in collaboration. Foster strong collaborations among researchers, project managers, and leadership. Clear decision-making criteria and shared objectives are vital to avoid derailment.
Build trust through transparency. Promote a culture of trust and self-awareness within the organization. Acknowledging scientific challenges and fostering honest discussion helps prevent internal teams from overstating their progress, which could later lead to external misalignment with investors

Scientific and portfolio reviews
Establish clear advancement criteria. For scientific teams, establish clear, evidence-based criteria for advancing a candidate through development stages. Activities for decision points can be run in parallel to increase efficiency and demonstrate a rigorous process.
Conduct portfolio-level assessment. View the pipeline as a whole. Utilize competitor analysis and market dynamics to allocate resources toward areas with more favorable commercial potential. This strategic approach helps manage overall risk and optimize returns across the portfolio.

Future Focus: Redefining Value in the Clinical Trial Economy

[Dex]: The clinical development landscape is evolving toward integrated, tech-enabled, and globally distributed models. Looking ahead, how do you see the convergence of finance, data science, and clinical innovation redefining value and return on investment in the next decade, and what role will Ashur Capital play in that transformation?

[Robert]: Based on its stated model, Ashur Capital is well-positioned to play a pivotal role in this transformation by leveraging its financial expertise, strategic approach, and focus on innovation.

Funding globally distributed models. By investing in companies with globally scalable technology platforms, Ashur can facilitate the expansion of integrated and distributed clinical models. This supports its portfolio companies in reaching broader patient populations and accessing diverse markets.

Investment in tech-enabled innovation. Ashur Capital, as a venture capital and private equity firm, can strategically invest in early stage companies that are developing the core technologies driving this change. Examples include decentralized trial platforms, AI driven trial optimization software, and real-world evidence analytics solutions.

Strategic partnerships. The firm’s focus on “strategic alliance with the right partner” positions it to act as a crucial connector. It can foster collaborations between promising tech startups, established biotech firms, and data science experts, creating integrated solutions that accelerate clinical development.

Active management and guidance. Ashur Capital’s “hands-on support” and “analyze, identify, advise, execute” mantra allow it to provide more than just capital. By actively advising its portfolio companies, it can ensure that clinical innovations are aligned with market needs, regulatory requirements, and the financial realities of scaling.

Capitalizing on the “innovation premium”. Ashur Capital’s stated focus on “The Innovation Premium” indicates it will prioritize investments that leverage these convergent trends to generate disproportionate returns. This means investing in companies that not only improve R&D but also fundamentally change the cost-benefit ratio of clinical development.

Engr. Dex Marco Tiu Guibelondo, B.Sc. Pharm, R.Ph., B.Sc. CpE

Editor-in-Chief, PharmaFEATURES

Join Proventa International’s Clinical Operations and Clinical Trial Supply Chain East Coast USA Strategy Meeting at Le Meridien Boston Cambridge, Massachusetts, USA on the 18th of November 2025 to learn more about Ashur Capital.